Grupo de Carcinogénesis Epitelial

Francisco Real Jefe de Grupo
T +34 917328000 (Ext 3660)
freal@cnio.es

Investigadores

Miriam Marqués

Becarios Post-doctorales

Elena del Pilar Andrada
Irene Felipe
Eleonora Lapi
Jaime Martínez de Villarreal
Cristina Segovia

Becarios Pre-Doctorales

Catalina Berca
Cristina Bodas
Sonia Corral
Auba Gayá
Irene Millán
María Ramal
Chengsi Wu

Técnicos de Laboratorio

Natalia Del Pozo
Leticia Rodríguez

Científico Visitante

Mark Kalisz

We focus on the molecular pathophysiology of pancreatic ductal adenocarcinoma (PDAC) and urothelial bladder carcinoma (UBC) using a disease-oriented approach. These tumours present very distinct clinical challenges. We learn from patient samples, cultured cells/organoids, and genetically modified mice. To translate the findings, we bring this knowledge to a “population” level leveraging on information and samples from large patient cohorts together with Núria Malats (CNIO).

PDAC has a dismal prognosis even when diagnosed early. We aim to dissect the molecular mechanisms involved in very early steps of tumour development, harnessing the excellent genetic mouse models available. A main hypothesis is that cell differentiation is an early and potent tumour suppressor mechanism. Understanding the contribution of early molecular events is crucial to design better strategies for prevention and early tumour detection.

UBC presents with very wide clinical and pathological heterogeneity. Our aim is to acquire knowledge about the underlying molecular pathways and to apply it for improved prediction of outcome and therapy.

Publicaciones

Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, Rimner A, Wu YL, Özgüroglu M, Lee KH, Kato T, de Wit M, Kurata T, Reck M, Cho BC, Senan S, Naidoo J, Mann H, Newton M, Thiyagarajah P, Antonia SJ (2022). Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 40, 1301-1311. Publicación CNIO.
de Andrés MP, Jackson RJ, Felipe I, Zagorac S, Pilarsky C, Schlitter AM, Martinez de Villareal J, Jang GH, Costello E, Gallinger S, Ghaneh P, Greenhalf W, Knösel T, Palmer DH, Ruemmele P, Weichert W, Buechler M, Hackert T, Neoptolemos JP, Notta F, Malats N, Martinelli P, Real FX. (2022). GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. Gut (in press). Publicación CNIO.
Suarez-Cabrera C, Estudillo L, Ramón-Gil E, Martínez-Fernández M, Peral J, Rubio C, Lodewijk I, Martín de Bernardo Á, García-Escudero R, Villacampa F, Duarte J, de la Rosa F, Castellano D, Guerrero-Ramos F, Real FX, Malats N, Paramio JM, Dueñas M (2022). BlaDimiR: A Urine-based miRNA Score for Accurate Bladder Cancer Diagnosis and Follow-up. Eur Urol (in press). Publicación CNIO.
Garcia-Carbonero R, Bazan-Peregrino M, Gil-Martín M, Álvarez R, Macarulla T, Riesco-Martinez MC, Verdaguer H, Guillén-Ponce C, Farrera-Sal M, Moreno R, Mato-Berciano A, Maliandi MV, Torres-Manjon S, Costa M, Del Pozo N, Martínez de Villarreal J, Real FX, Vidal N, Capella G, Alemany R, Blasi E, Blasco C, Cascalló M, Salazar R. (2022). Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. J Immunother Cancer 10, e003255. Publicación CNIO.
Chondronasiou D, Martínez de Villarreal J, Melendez E, Lynch CJ, Pozo ND, Kovatcheva M, Aguilera M, Prats N, Real FX, Serrano M. (2022). Deciphering the roadmap of in vivo reprogramming toward pluripotency. Stem Cell Reports (in press). Publicación CNIO.
Melendez E, Chondronasiou D, Mosteiro L, Martínez de Villarreal J, Fernández-Alfara M, Lynch CJ, Grimm D, Real FX, Alcamí J, Climent N, Pietrocola F, Serrano M. (2022). Natural killer cells act as an extrinsic barrier for in vivo reprogramming. Development 149, dev200361. Publicación CNIO.
Real FX, Siveke JT. (2021). Pancreatic cancer transcriptomes: molecular stratification in the adjuvant setting.. Ann Oncol 32, 133-135. Publicación CNIO.
Kloesch B, Ionasz V, Paliwal S, Hruschka N, Martinez de Villarreal J, Öllinger R, Mueller S, Dienes HP, Schindl M, Gruber ES, Stift J, Herndler-Brandstetter D, Lomberk GA, Seidler B, Saur D, Rad R, Urrutia RA, Real FX, Martinelli P. (2021). A GATA6-centred gene regulatory network involving HNFs and ?Np63 controls plasticity and immune escape in pancreatic cancer. Gut (in press). Publicación CNIO.
Martens S, Coolens K, Van Bulck M, Arsenijevic T, Casamitjana J, Fernandez Ruiz A, El Kaoutari A, Martinez de Villareal J, Madhloum H, Esni F, Heremans Y, Leuckx G, Heimberg H, Bouwens L, Jacquemin P, De Paep DL, In't Veld P, D'Haene N, Bouchart C, Dusetti N, Van Laethem JL, Waelput W, Lefesvre P, Real FX, Rovira M, Rooman I. (2021). Discovery and 3D imaging of a novel ?Np63-expressing basal cell type in human pancreatic ducts with implications in disease. Gut (in press). Publicación CNIO.
Molina-Montes E, Coscia C, Gómez-Rubio P, Fernández A, Rianne Boenink R, Rava M, Márquez M, Molero X, Löhr M, Sharp L, Michalski CW, Farré A, Perea J, O'Rorke M, Greenhalf W, Iglesias M, Tardón A, Gress T, Barberà VM, Crnogorac-Jurcevic T, Muñoz-Bellvís L, Domínguez-Muñoz E, Harald Renz H, Balsells J, Costello E, Ilzarbe L, Jörg Kleeff J, Kong B, Mora J, O'Driscoll D, Poves I, Scarpa A, Yu J, Hidalgo M, Lawlor RT, Ye W, Carrato A, Real FX, Malats N, on behalf of the PanGenEU Study Investigators (2021). Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes, and obesity/BMI through causal inference and mediation analyses.. Gut 70, 319-329. Publicación CNIO.
Richart L, Lapi E, Pancaldi V, Cuenca-Ardura M, Pau EC, Madrid-Mencía M, Neyret-Kahn H, Radvanyi F, Rodríguez JA, Cuartero Y, Serra F, Le Dily F, Valencia A, Marti-Renom MA, Real FX. (2021). STAG2 loss-of-function affects short-range genomic contacts and modulates the basal-luminal transcriptional program of bladder cancer cells. Nucleic Acids Res 49, 11005-11021. Publicación CNIO. Open Access
Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtröder K, Jensen JB, Strandgaard T, Nordentoft I, Christensen E, Sokac M, Birkbak NJ, Maretty L, Hermann GG, Petersen AC, Weyerer V, Grimm MO, Horstmann M, Sjödahl G, Höglund M, Steiniche T, Mogensen K, de Reyniès A, Nawroth R, Jordan B, Lin X, Dragicevic D, Ward DG, Goel A, Hurst CD, Raman JD, Warrick JI, Segersten U, Sikic D, van Kessel KEM, Maurer T, Meeks JJ, DeGraff DJ, Bryan RT, Knowles MA, Simic T, Hartmann A, Zwarthoff EC, Malmström PU, Malats N, Real FX, Dyrskjøt L (2021). An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun 1, 2301. Publicación CNIO.
Jermusyk A, Zhong J, Connelly KE, Gordon N, Perera S, Abdolalizadeh E, Zhang T, O'Brien A, Hoskins JW, Collins I, Eiser D, Yuan C; PanScan Consortium; PanC4 Consortium, Risch HA, Jacobs EJ, Li D, Du M, Stolzenberg-Solomon RZ, Klein AP, Smith JP, Wolpin BM, Chanock SJ, Shi J, Petersen GM, Westlake CJ, Amundadottir LT (2021). A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. Am J Hum Genet 108, 1852-1865. Publicación CNIO.
López de Maturana E, Rodríguez JA, Alonso L, Lao O, Molina-Montes E, Martín-Antoniano IA, Gómez-Rubio P, Lawlor R, Carrato A, Hidalgo M, Iglesias M, Molero X, Löhr M, Michalski C, Perea J, O'Rorke M, Barberà VM, Tardón A, Farré A, Muñoz-Bellvís L, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Gress T, Greenhalf W, Sharp L, Arnes L, Cecchini L, Balsells J, Costello E, Ilzarbe L, Kleeff J, Kong B, Márquez M, Mora J, O'Driscoll D, Scarpa A, Ye W, Yu J; PanGenEU Investigators, García-Closas M, Kogevinas M, Rothman N, Silverman DT; SBC/EPICURO Investigators, Albanes D, Arslan AA, Beane-Freeman L, Bracci PM, Brennan P, Bueno-de-Mesquita B, Buring J, Canzian F, Du M, Gallinger S, Gaziano JM, Goodman PJ, Gunter M, LeMarchand L, Li D, Neale RE, Peters U, Petersen GM, Risch HA, Sánchez MJ, Shu XO, Thornquist MD, Visvanathan K, Zheng W, Chanock SJ, Easton D, Wolpin BM, Stolzenberg-Solomon RZ, Klein AP, Amundadottir LT, Marti-Renom MA, Real FX, Malats N (2021). A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Genome Med 13, 15. Publicación CNIO.
Vangala D, Ladigan S, Liffers ST, Noseir S, Maghnouj A, Götze TM, Verdoodt B, Klein-Scory S, Godfrey L, Zowada MK, Huerta M, Edelstein DL, de Villarreal JM, Marqués M, Kumbrink J, Jung A, Schiergens T, Werner J, Heinemann V, Stintzing S, Lindoerfer D, Mansmann U, Pohl M, Teschendorf C, Bernhardt C, Wolters H, Stern J, Usta S, Viebahn R, Admard J, Casadei N, Fröhling S, Ball CR, Siveke JT, Glimm H, Tannapfel A, Schmiegel W, Hahn SA (2021). Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.. Genome Med 13, 116. Publicación CNIO.
Cobo I, Iglesias M, Flández M, Verbeke C, del Pozo N, Llorente M, Lawlor R, Luchini C, Rusev B, Scarpa A, Real FX (2021). Epithelial Nr5a2 pancreatic haploinsufficiency cooperates with mutant Kras in the development of pancreatic cystic tumors.. J Pathol 253, 174-185. Publicación CNIO.
Yu J, Ploner A, Kordes M, Löhr M, Nilsson M, de Maturana MEL, Estudillo L, Renz H, Carrato A, Molero X (2021). Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma. Int J Cancer 148, 2048-2058. Publicación CNIO.
Malinova A, Veghini L, Real FX, Corbo V (2021). Cell Lineage Infidelity in PDAC Progression and Therapy Resistance. Front Cell Dev Biol 9, 795251. Publicación CNIO.
Cáceres M, Quesada R, Iglesias M, Real FX, Villamonte M, de Villarreal JM, Pérez M, Andaluz A, Moll X, Berjano E, Dorcaratto D, Sánchez-Velázquez P, Grande L, Burdío F (2021). Publisher Correction: Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic adenocarcinoma in mice. Sci Rep 11, 5425. Publicación CNIO.
Rosato V, Gómez-Rubio P, Molina-Montes E, Márquez M, Löhr M, O'Rorke M, Michalski CW, Molero X, Farré A, Perea J, Kleeff J, Crnogorac-Jurcevic T, Greenhalf W, Ilzarbe L, Tardón A, Gress T, Barberá VM, Domínguez-Muñoz E, Muñoz-Bellvís L, Balsells J, Costello E, Iglesias M, Kong B, Mora J, O'Driscoll D, Poves I, Scarpa A, Ye W, Hidalgo M, Sharp L, Carrato A, Real FX, La Vecchia C, Malats N; PanGenEU Study Investigators. (2021). Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. Eur J Cancer Prev 30, 423-430. Publicación CNIO.
Colom B, Alcolea MP, Piedrafita G, Hall MWJ, Wabik A, Dentro SC, Fowler JC, Herms A, King C, Ong SH, Sood RK, Gerstung M, Martincorena I, Hall BA, Jones PH (2020). Spatial Competition Shapes the Dynamic Mutational Landscape of Normal Esophageal Epithelium. Nat Genet 52, 604-614. Publicación CNIO.
Kamoun A, Reyniès A, Allory Y, Sjödahl G, Gordon Robertson A, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F; Bladder Cancer Molecular Taxonomy Group (2020). A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol 77, 420-423. Publicación CNIO.
van Rhijn BWG et al. (incl. Real FX) (2020). FGFR3 mutation and FGFR3 expression in a large bladder cancer cohort treated by radical cystectomy: Implications for anti-FGFR3 treatment?. Eur Urol 78, 682-687. Publicación CNIO.
Piedrafita G, Kostiou V, Wabik A, Colom B, Fernandez-Antoran D, Herms A, Murai K, Hall BA, Jones PH (2020). A single-progenitor model as the unifying paradigm of epidermal and esophageal epithelial maintenance in mice.. Nat Commun 11, 1429. Publicación CNIO. Open Access
Marqués M, Tranchant R, Risa-Ebrí B, Suárez-Solís ML, Fernández LC, Carrillo-de-Santa-Pau E, Del Pozo N, Martínez de Villarreal J, Meiller C, Allory Y, Blum Y, Pirker C, Hegedus B, Barry ST, Carnero A, Berger W, Jean D, Real FX. (2020). Combined MEK and PI3K/p110ß Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.. Cancer Res 80, 843-856. Publicación CNIO.
Yuan F, Hung RJ, Walsh N, Zhang H, Platz EA, Wheeler W, Song L, Arslan AA, Beane Freeman LE, Bracci P, Canzian F, Du M, Gallinger S, Giles GG, Goodman PJ, Kooperberg C, Le Marchand L, Neale RE, Rosendahl J, Scelo G, Shu XO, Visvanathan K, White E, Zheng W, Albanes D, Amiano P, Andreotti G, Babic A, Bamlet WR, Berndt SI, Brennan P, Bueno-de-Mesquita B, Buring JE, Campbell PT, Chanock SJ, Fuchs CS, Gaziano JM, Goggins MG, Hackert T, Hartge P, Hassan MM, Holly EA, Hoover RN, Katzke V, Kirsten H, Kurtz RC, Lee IM, Malats N, Milne R, Murphy N, Ng K, Oberg AL, Porta M, Rabe KG, Real FX, Rothman N, Sesso HD, Silverman DT, Thompson IM, Wactawski-Wende J, Wang X, Wentzensen N, Wilkens LR, Yu H, Zeleniuch-Jacquotte A, Shi J, Duell EJ, Amundadottir LT, Li D, Petersen GM, Wolpin BM, Risch HA, Yu K, Klein AP, Stolzenberg-Solomon R (2020). Genome-wide association study data reveal genetic susceptibility to chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma risk. Cancer Res 80, 4004-4013. Publicación CNIO.
Debernardi S, O'Brien H, Algahmdi AS, Malats N, Real FX, Stewart G, Plješa-Ercegovac M, Costello E, Greenhalf W, Saad A, Roberts R, Ney A, Pereira SP, Kocher HM, Duffy S, Blyuss O, Crnogorac-Jurcevic T (2020). A Combination of Urinary Biomarker Panel and PancRISK Score for Earlier Detection of Pancreatic Cancer. PLoS Med 17, e1003489. Publicación CNIO.
Kalisz M, Bernardo E, Beucher A, Maestro MA, Del Pozo N, Millán I, Haeberle L, Schlensog M, Safi SA, Knoefel WT, Grau V, de Vas M, Shpargel KB, Vaquero E, Magnuson T, Ortega S, Esposito I, Real FX, Ferrer J (2020). HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer.. EMBO J 39, e102808. Publicación CNIO.
De Koninck M, Lapi E, Badía-Careaga C, Cossío I, Giménez-Llorente D, Rodríguez-Corsino M, Andrada E, Hidalgo A, Manzanares M, Real FX, Losada A (2020). Essential Roles of Cohesin STAG2 in Mouse Embryonic Development and Adult Tissue Homeostasis.. Cell Reports 32, 108014. Publicación CNIO. Open Access
Hruschka N, Kalisz M, Subijana M, Graña-Castro O, Del Cano-Ochoa F, Brunet LP, Chernukhin I, Sagrera A, De Reynies A, Kloesch B, Chin SF, Burgués O, Andreu D, Bermejo B, Cejalvo JM, Sutton J, Caldas C, Ramón-Maiques S, Carroll JS, Prat A, Real FX, Martinelli P (2020). The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver. Oncogene 39, 5455-5467. Publicación CNIO.
Richart L, Felipe I, Delgado P, Andrés MP, Prieto J, Pozo ND, García JF, Piris MA, Ramiro A, Real FX. (2020). Bptf determines oncogenic addiction in aggressive B-cell lymphomas. Oncogene 39, 4884-4895. Publicación CNIO.
Rodríguez-Seguel E, Villamayor L, Arroyo N, de Andrés MP, Real FX, Martín F, Cano DA, Rojas A (2020). Loss of GATA4 causes ectopic pancreas in the stomach. J Pathol 250, 362-373. Publicación CNIO.
Font A, Domènech M, Benítez R, Rava M, Marqués M, Ramírez JL, Pineda S, Domínguez-Rodríguez S, Gago JL, Badal J, Carrato C, López H, Quer A, Castellano D, Malats N, Real FX (2020). Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy. Cancers 12, 1784. Publicación CNIO. Open Access
Martinez-Font E, Pérez-Capó M, Ramos R, Felipe I, Garcías C, Luna P, Terrasa J, Martín-Broto J, Vögler O, Alemany R, Obrador-Hevia A (2020). Impact of Wnt/ß-Catenin Inhibition on Cell Proliferation through CDC25A Downregulation in Soft Tissue Sarcomas. Cancers 12, E2556. Publicación CNIO. Open Access
Fernández-Barral A, Costales-Carrera A, Buira SP, Jung P, Ferrer-Mayorga G, Larriba MJ, Bustamante-Madrid P, Domínguez O, Real FX, Guerra-Pastrián L, Lafarga M, García-Olmo D, Cantero R, Del Peso L, Batlle E, Rojo F, Muñoz A, Barbáchano A. (2020). Vitamin D differentially regulates colon stem cells in patient-derived normal and tumor organoids.. FEBS J 287, 53-72. Publicación CNIO.
Cáceres M, Quesada R, Iglesias M, Real FX, Villamonte M, Martínez de Villarreal J, de Andrés MP, Andaluz A, Berjano E, Dorcaratto D, Sánchez-Velázquez P, Grande L, Burdío F (2020). Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic adenocarcinoma in mice.. Sci Rep 10, 18344. Publicación CNIO.
Molina-Montes E, Van Hoogstraten L, Gomez-Rubio P, Löhr M, Sharp L, Molero X, Márquez M, Michalski CW, Farré A, Perea J, O'Rorke M, Greenhalf W, Ilzarbe L, Tardon A, Gress TM, Barberà VM, Crnogorac-Jurcevic T, Muñoz-Bellvis L, Domínguez-Muñoz E, Balsells J, Costello E, Iglesias M, Kleeff J, Kong B, Mora J, O'Driscoll D, Poves I, Scarpa A, Yu J, Ye W, Hidalgo M, Carrato A, Lawlor R, Real FX, Malats N; PanGenEU Study Investigators. (2020). Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. Cancer Epidem Biomar 29, 1009-1018. Publicación CNIO.
Prades J, Arnold S, Brunner T, Cardone A, Carrato A, Coll-Ortega C, De Luze S, Garel P, Goossens M, Grilli R, Harris M, Louage M, Malats N, Partelli S, Pastorekova S, Petrulionis M, Price R, Sclafani F, Smolkova B, Borras JM (2020). The Bratislava Statement: consensus recommendations for improving pancreatic cancer care.. ESMO OPEN 5, e001051. Publicación CNIO.
Zhou W, Machiela MJ, Freedman ND, Rothman N, Malats N, Dagnall C, Caporaso N, Teras LT, Gaudet MM, Gapstur SM, Stevens VL, Jacobs KB, Sampson J, Albanes D, Weinstein S, Virtamo J, Berndt S, Hoover RN, Black A, Silverman D, Figueroa J, Garcia-Closas M, Real FX, Earl J, Marenne G, Rodriguez-Santiago B, Karagas M, Johnson A, Schwenn M, Wu X, Gu J, Ye Y, Hutchinson A, Tucker M, Perez-Jurado LA, Dean M, Yeager M, Chanock SJ (2019). Reply to ‘Mosaic loss of chromosome Y in leukocytes matters’. Nat Genet 51, 7-9. Publicación CNIO.
Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, Fristrup CW, Mortensen MB, Žakelj MP, Zadnik V, Becker N, Hackert T, Magi M, Cassetti T, Sassatelli R, Grützmann R, Merkel S, Gonçalves AF, Bento MJ, Hegyi P, Lakatos G, Szentesi A, Moreau M, van de Velde T, Broeks A, Real FX, Carrato A, Molero X, Besselink MG, Malats N, Büchler MW, Schrotz-King P, Brenner H (2019). Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut 68, 130-139. Publicación CNIO.
Santos CP, Lapi E, Martínez de Villarreal J, Álvaro-Espinosa L, Fernández-Barral A, Barbáchano A, Domínguez O, Laughney AM, Megías D, Muñoz A, Real FX (2019). Urothelial organoids originating from Cd49fhigh mouse stem cells display Notch-dependent differentiation capacity. Nat Commun 10, 4407. Publicación CNIO. Open Access
Walsh N, Zhang H, Hyland PL, Yu K, Yang Q, ... Real FX,... Stolzenberg-Solomon, R (2019). Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. J Natl Cancer I 111, 557-567. Publicación CNIO.
Rubio C, Martínez-Fernández M, Segovia C, Lodewijk I, Suarez-Cabrera C, Segrelles C, López-Calderón F, Munera-Maravilla E, Santos M, Bernardini A, García-Escudero R, Lorz C, Gómez-Rodriguez MJ, de Velasco G, Otero I, Villacampa F, Guerrero-Ramos F, Ruiz S, de la Rosa F, Domínguez-Rodríguez S, Real FX, Malats N, Castellano D, Dueñas M, Paramio JM (2019). CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status. Clin Cancer Res 25, 390-402. Publicación CNIO.
Xu W, Long L, Zhao Y, Stevens L, Felipe I, Munoz J, Ellis RE, McGrath PT (2019). Evolution of Yin and Yang isoforms of a chromatin remodeling subunit precedes the creation of two genes.. Elife 8, e48119. Publicación CNIO. Open Access
Gomez-Rubio P, Piñero J, Molina-Montes E, Gutiérrez-Sacristán A, Marquez M, Rava M, Michalski CW, Farré A, Molero X, Löhr M, Perea J, Greenhalf W, O'Rorke M, Tardón A, Gress T, Barberá VM, Crnogorac-Jurcevic T, Muñoz-Bellvís L, Domínguez-Muñoz E, Balsells J, Costello E, Yu J, Iglesias M, Ilzarbe L, Kleeff J, Kong B, Mora J, Murray L, O'Driscoll D, Poves I, Lawlor RT, Ye W, Hidalgo M, Scarpa A, Sharp L, Carrato A, Real FX, Furlong LI, Malats N; PanGenEU Study Investigators (2019). Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. Int J Cancer 144, 1540-1549. Publicación CNIO.
Masson-Lecomte A, Maillé P, Pineda S, Soyeux P, Sagrera A, Rava M, Lopez de Maturana E, Márquez M, Tardón A, Carrato A, Kogevinas M, de la Taille A, Hartmann A, Real FX, Malats N, Allory Y (2019). CD8+ Cytotoxic inflammatory infiltrate in non-muscle invasive bladder cancer: a standardized methodology to study association with prognosis and clinico-pathological features. Bladder Cancer 5, 159-169. Publicación CNIO.
Martinelli P, Real FX (2019). Mouse Models Shed Light on the SLIT/ROBO Pathway in Pancreatic Development and Cancer. Trends in Cancer 5, 145-148. Publicación CNIO.
Cobo I, Martinelli P, Flández M, Bakiri L, Zhang M, Carrillo-de-Santa-Pau E, Jia J, Sánchez-Arévalo Lobo VJ, Megías D, Felipe I, Del Pozo N, Millán I, Thommesen L, Bruland T, Olson SH, Smith J, Schoonjans K, Bamlet WR, Petersen GM, Malats N, Amundadottir LT, Wagner EF, Real FX (2018). Transcriptional regulation by NR5A2 links differentiation and inflammation in the pancreas. Nature 554, 533-537. Publicación CNIO.
European Study Group on Cystic Tumours of the Pancreas (2018). European evidence-based guidelines on pancreatic cystic neoplasms. Gut 67, 789-804. Publicación CNIO.
Sánchez-Arévalo Lobo VJ, Fernández LC, Carrillo-de-Santa-Pau E, Richart L, Cobo I, Cendrowski J, Moreno U, Del Pozo N, Megías D, Bréant B, Wright CV, Magnuson M, Real FX (2018). c-Myc downregulation is required for preacinar to acinar maturation and pancreatic homeostasis. Gut 67, 707-718. Publicación CNIO.
Scarpa A, Real FX, Luchini C (2018). Genetic unrelatedness of co-occurring pancreatic adenocarcinomas and IPMNs challenges current views of clinical management. Gut 67, 1561-1563. Publicación CNIO.
Klein AP, Wolpin BM, Risch HA, Stolzenberg-Solomon RZ, Mocci E, Zhang M, Canzian F, Childs EJ, Hoskins JW, Jermusyk A, Zhong J, Chen F, Albanes D, Andreotti G, Arslan AA, Babic A, Bamlet WR, Beane-Freeman L, Berndt SI, Blackford A, Borges M, Borgida A, Bracci PM, Brais L, Brennan P, Brenner H, Bueno-de-Mesquita B, Buring J, Campa D, Capurso G, Cavestro GM, Chaffee KG, Chung CC, Cleary S, Cotterchio M, Dijk F, Duell EJ, Foretova L, Fuchs C, Funel N, Gallinger S, M Gaziano JM, Gazouli M, Giles GG, Giovannucci E, Goggins M, Goodman GE, Goodman PJ, Hackert T, Haiman C, Hartge P, Hasan M, Hegyi P, Helzlsouer KJ, Herman J, Holcatova I, Holly EA, Hoover R, Hung RJ, Jacobs EJ, Jamroziak K, Janout V, Kaaks R, Khaw KT, Klein EA, Kogevinas M, Kooperberg C, Kulke MH, Kupcinskas J, Kurtz RJ, Laheru D, Landi S, Lawlor RT, Lee IM, LeMarchand L, Lu L, Malats N, Mambrini A, Mannisto S, Milne RL, Mohelníková-Duchonová B, Neale RE, Neoptolemos JP, Oberg AL, Olson SH, Orlow I, Pasquali C, Patel AV, Peters U, Pezzilli R, Porta M, Real FX, Rothman N, Scelo G, Sesso HD, Severi G, Shu XO, Silverman D, Smith JP, Soucek P, Sund M, Talar-Wojnarowska R, Tavano F, Thornquist MD, Tobias GS, Van Den Eeden SK, Vashist Y, Visvanathan K, Vodicka P, Wactawski-Wende J, Wang Z, Wentzensen N, White E, Yu H, Yu K, Zeleniuch-Jacquotte A, Zheng W, Kraft P, Li D, Chanock S, Obazee O, Petersen GM, Amundadottir LT (2018). Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nat Commun 9, 556. Publicación CNIO. Open Access
Alemany R, Moura DS, Redondo A, Martinez-Trufero J, Calabuig S, Saus C, Obrador-Hevia A, Ramos R, Villar VH, Valverde C, Vaz MA, Medina J, Felipe-Abrio I, Hindi N, Taron M, Martin-Broto J (2018). Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma. Clin Cancer Res 24, 5239-5249. Publicación CNIO.
van Kessel KEM, van der Keur KA, Dyrskjøt L, Algaba F, Welvaart NYC, Beukers W, Segersten U, Keck B, Maurer T, Simic T, Horstmann M, Grimm MO, Hermann GG, Mogensen K, Hartmann A, Harving N, Petersen AC, Jensen JB, Junker K, Boormans JL, Real FX, Malats N, Malmström PU, Ørntoft TF, Zwarthoff EC (2018). Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups. Clin Cancer Res 24, 1586-1593. Publicación CNIO.
Molina-Montes E, Gomez-Rubio P, Márquez M, Rava M, Löhr M, Michalski CW, Molero X, Farré A, Perea J, Greenhalf W, Ilzarbe L, O'Rorke M, Tardón A, Gress T, Barberà VM, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Muñoz-Bellvís L, Balsells J, Costello E, Huang J, Iglesias M, Kleeff J, Kong B, Mora J, Murray L, O'Driscoll D, Poves I, Scarpa A, Ye W, Hidalgo M, Sharp L, Carrato A, Real FX, Malats N; PanGenEU Study Investigators (2018). Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. Int J Epidemiol 47, 473-483. Publicación CNIO.
Villamayor L, Rodríguez-Seguel E, Araujo R, Carrasco M, Bru-Tarí E, Mellado-Gil JM, Gauthier BR, Martinelli P, Quesada I, Soria B, Martín F, Cano DA, Rojas A (2018). GATA6 Controls Insulin Biosynthesis and Secretion in Adult ß-Cells. Diabetes 67, 448-460. Publicación CNIO.
Rava M, Czachorowski MJ, Silverman D, Márquez M, Kishore S, Tardón A, Serra C, García-Closas M, Garcia-Closas R, Carrato A, Rothman N, Real FX, Kogevinas M, Malats N (2018). Asthma status is associated with decreased risk of aggressive urothelial bladder cancer. Int J Cancer 42, 470-476. Publicación CNIO.
Real FX, de Andrés MP (2018). Mutant Kras Dosage and Chromothripsis: The Right Ingredients for a Pancreatic Cancer Catastrophe. Trends in Cancer 4, 399-401. Publicación CNIO.
Choi W, Ochoa A, McConkey DJ, Aine M, Höglund M, Kim WY, Real FX, Kiltie AE, Milsom I, Dyrskjøt L, Lerner SP (2017). Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 72, 354-365. Publicación CNIO.
Dyrskjøt L, Reinert T, Algaba F, Christensen E, Nieboer D, Hermann GG, Mogensen K, Marquez M, Segersten U, Høyer S, Ulhøi BP, Hartmann A, Stöhr R, Wach S, Nawroth R, Schwamborn K, Tulic K, Simic T, Junker K, Harving N, Petersen AC, Jensen JB, Keck B, Horstmann M, Maurer T, Steyerberg EW, Zwarthoff EC, Real EX, Malats N, Malmström PU, Ørntoft TF (2017). Prognostic impact of a 12-gene progression score in non-muscle invasive bladder cancer: a prospective multicenter validation study. Eur Urol 72, 461-469. Publicación CNIO.
Gomez-Rubio P, Rosato V, Marquez M, Bosetti C, Molina-Montes E, Rava M, Piñero J, Michalski CW, Farré A, Molero X, Löhr M, Ilzarbe L, Perea J, Greenhalf W, O'Rorke M, Tardón A, Gress T, Barberà VM, Crnogorac-Jurcevic T, Muñoz-Bellvís L, Domínguez-Muñoz E, Gutiérrez-Sacristán A, Balsells J, Costello E, Guillén-Ponce C, Huang J, Iglesias M, Kleeff J, Kong B, Mora J, Murray L, O'Driscoll D, Peláez P, Poves I, Lawlor RT, Carrato A, Hidalgo M, Scarpa A, Sharp L, Furlong LI, Real FX, La Vecchia C, Malats N; PanGenEU Study Investigators (2017). A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. Ann Oncol 28, 1618-1624. Publicación CNIO.
Gómez-Rubio P, Zock JP, Rava M, Marquez M, Sharp L, Hidalgo M, Carrato A, Ilzarbe L, Michalski C, Molero X, Farré A, Perea J, Greenhalf W, O'Rorke M, Tardón A, Gress T, Barberà V, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Muñoz-Bellvís L, Alvarez-Urturi C, Balcells J, Barneo L, Costello E, Guillén-Ponce C, Kleeff J, Kong B, Lawlor R, Löhr M, Mora J, Murray L, O'Driscoll D, Peláez P, Poves I, Scarpa A, Real FX, Malats N; PanGenEU Study Investigators (2017). Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Gut 66, 314-322. Publicación CNIO.
Marqués M, Real FX (2017). PIcKing on Fibroblast Growth Factor Receptors as Bladder Cancer Therapeutic Targets. Eur Urol 17, 863-865. Publicación CNIO.
Martinelli P, Carrillo-de Santa Pau E, Cox T, Sainz B Jr, Dusetti N5 Greenhalf W, Rinaldi L, Costello E, Ghaneh P, Malats N, Büchler M, Pajic M, Biankin AV, Iovanna J, Neoptolemos J, Real FX (2017). GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut 66, 1665-1676. Publicación CNIO.
Notta F, Hahn SA, Real FX (2017). A genetic roadmap of pancreatic cancer: still evolving. Gut 66, 2170-2178. Publicación CNIO.
Van der Lelij P, Lieb S, Jude J, Witz G, Santos CP, Falkenberg K, Schlattl A, Ban J, Schwentner R, Kovar H, Real FX, Waldman T, Pearson M, Kraut N, Peters JM, Zuber J, Petronczki M (2017). Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts. Elife 6, e26980. Publicación CNIO. Open Access
Beukers W, van der Keur KA, Kandimalla R, Vergouwe Y, Steyerberg EW, Boormans JL, Jensen JB, Lorente JA, Real FX, Segersten U, Orntoft TF, Malats N, Malmström PU, Dyrskjot L, Zwarthoff EC (2017). FGFR3, TERT and OTX1 as a urinary biomarker combination for surveillance of patients with bladder cancer in a large prospective multicenter study. J Urology 197, 1410-1418. Publicación CNIO.
van Kessel KE, Beukers W, Lurkin I, Ziel-van der Made A, van der Keur KA, Boormans JL, Dyrskjøt L, Márquez M, Ørntoft TF, Real FX, Segersten U, Malats N, Malmström PU, Van Criekinge W, Zwarthoff EC (2017). Validation of a DNA methylation-mutation urine assay to select patients with hematuria for cystoscopy. J Urology 197, 590-595. Publicación CNIO.